[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @FidelisAurelius Fidelis Aurelius Fidelis Aurelius posts on X about $srpt, $sln, events, if you the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1368807348/interactions)  - X Week XXXXX +109% - X Month XXXXXX -XX% - X Months XXXXXXX +412% - X Year XXXXXXX +483% ### Mentions: X [#](/creator/twitter::1368807348/posts_active)  - X Week XX -XX% - X Month XX +28% - X Months XXX +76% - X Year XXX +12% ### Followers: XXX [#](/creator/twitter::1368807348/followers)  - X Week XXX +0.83% - X Month XXX +6.10% - X Months XXX +81% - X Year XXX +348% ### CreatorRank: undefined [#](/creator/twitter::1368807348/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [fashion brands](/list/fashion-brands) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [$srpt](/topic/$srpt) 14.29%, [$sln](/topic/$sln) 7.14%, [events](/topic/events) 7.14%, [if you](/topic/if-you) 7.14%, [new balance](/topic/new-balance) 7.14%, [hola](/topic/hola) 7.14%, [future](/topic/future) 7.14%, [gain](/topic/gain) 7.14%, [$rnas](/topic/$rnas) 7.14%, [one piece](/topic/one-piece) XXXX% **Top accounts mentioned or mentioned by** [@charle77238](/creator/undefined) [@wassimlaroussi3](/creator/undefined) [@commonsenseplay](/creator/undefined) [@mrhighwayy](/creator/undefined) [@qcapital2020](/creator/undefined) [@pick19982](/creator/undefined) [@genejchan](/creator/undefined) [@bronxb_13](/creator/undefined) [@veevi24](/creator/undefined) **Top assets mentioned** [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Smart Layer Network (SLN)](/topic/$sln) ### Top Social Posts Top posts by engagements in the last XX hours "$SLN I think this will be a winner. The PV program has a high PoS with near term calendar events. The Lp(a) program is a free call option waiting for either partner or class-level win from others in the field. My rNPV says this is worth about 1.8B 1.5B for PV 300M for Lp(a) without considering the platform value" [X Link](https://x.com/FidelisAurelius/status/1978884099164246502) 2025-10-16T18:01Z XXX followers, XXX engagements "@commonsenseplay @mrhighway_y Sarepta is now an siRNA story in X crowded fields (DM1/FSHD). Their DMD drugs don't work they are expensive placebos. If you care about DMD at all read this" [X Link](https://x.com/FidelisAurelius/status/1997851420373266860) 2025-12-08T02:11Z XXX followers, XXX engagements "@qcapital2020 Have you been to any sports store Hola and New Balance are everywhere. Stores are putting Hoka first before Nike" [X Link](https://x.com/FidelisAurelius/status/1998395223106617431) 2025-12-09T14:12Z XXX followers, 4201 engagements "@charle77238 The company has to prove itself. I don't make excuses for their crappy share price. They will have to prove themselves by executing and presenting more data. I believe things can change if they show us sustained strength and ppFVC improvement in the adults cohort next Q" [X Link](https://x.com/FidelisAurelius/status/1999095759745294454) 2025-12-11T12:35Z XXX followers, XX engagements "@pick1998_2 Bro $SRPT does not reverse the disease progress. Best it can do is halt. And year X data is already faltering" [X Link](https://x.com/FidelisAurelius/status/1996386900672995600) 2025-12-04T01:11Z XXX followers, XXX engagements "@genejchan DMD is not within his field of competence. He talked up/long $SRPT. If he were competent in this field he would short it not long it" [X Link](https://x.com/FidelisAurelius/status/1996751891313971216) 2025-12-05T01:22Z XXX followers, XXX engagements "The future is complementary. CAPR does not bring back muscles and functions MSCLF can and the early results spoke for themselves. Soon we will know if the adults can sustain and gain more and P2 is starting in days with blinded interim in Q2. In an ideal world we could have the patients live into old age if both drugs work" [X Link](https://x.com/FidelisAurelius/status/1998922957989752913) 2025-12-11T01:09Z XXX followers, XXX engagements "@charle77238 There is a budget in their disclosure on Canadian side. They are guiding for 33M spending for P2 and leaving out a couple millions in reserve. So they have the cash. If they are short on cash I would never recommend" [X Link](https://x.com/FidelisAurelius/status/1999089125467807948) 2025-12-11T12:09Z XXX followers, XX engagements "So $RNA's exon44 functional data just dropped. NSAA change from baseline is ZERO in an open label setting. Knowing open label data typically outperform in open label what would have happened if this was RCT I dare say they would have failed. Critically how is is possible that an exon skipper with average expression of 30%+ with some patients reaching as high as 50%+ fail to show ANY functional benefit at all in NSAA Remember this is well into Beckers territory if not beyond. If exonskipping or uDys or any drug that is built on the membrane stability hypothesis could bring function back this" [X Link](https://x.com/FidelisAurelius/status/1995685763099263193) 2025-12-02T02:45Z XXX followers, XXX engagements "$MSCLF's 2nd indication will be FSHD. They did have mice data showing strength improvements but to me DMD is the clear shot on goal. The rest is optionality/platform value" [X Link](https://x.com/FidelisAurelius/status/1999332710901514580) 2025-12-12T04:17Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@FidelisAurelius Fidelis AureliusFidelis Aurelius posts on X about $srpt, $sln, events, if you the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence stocks XXXXX% cryptocurrencies XXXX% fashion brands XXXX% finance XXXX%
Social topic influence $srpt 14.29%, $sln 7.14%, events 7.14%, if you 7.14%, new balance 7.14%, hola 7.14%, future 7.14%, gain 7.14%, $rnas 7.14%, one piece XXXX%
Top accounts mentioned or mentioned by @charle77238 @wassimlaroussi3 @commonsenseplay @mrhighwayy @qcapital2020 @pick19982 @genejchan @bronxb_13 @veevi24
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Smart Layer Network (SLN)
Top posts by engagements in the last XX hours
"$SLN I think this will be a winner. The PV program has a high PoS with near term calendar events. The Lp(a) program is a free call option waiting for either partner or class-level win from others in the field. My rNPV says this is worth about 1.8B 1.5B for PV 300M for Lp(a) without considering the platform value"
X Link 2025-10-16T18:01Z XXX followers, XXX engagements
"@commonsenseplay @mrhighway_y Sarepta is now an siRNA story in X crowded fields (DM1/FSHD). Their DMD drugs don't work they are expensive placebos. If you care about DMD at all read this"
X Link 2025-12-08T02:11Z XXX followers, XXX engagements
"@qcapital2020 Have you been to any sports store Hola and New Balance are everywhere. Stores are putting Hoka first before Nike"
X Link 2025-12-09T14:12Z XXX followers, 4201 engagements
"@charle77238 The company has to prove itself. I don't make excuses for their crappy share price. They will have to prove themselves by executing and presenting more data. I believe things can change if they show us sustained strength and ppFVC improvement in the adults cohort next Q"
X Link 2025-12-11T12:35Z XXX followers, XX engagements
"@pick1998_2 Bro $SRPT does not reverse the disease progress. Best it can do is halt. And year X data is already faltering"
X Link 2025-12-04T01:11Z XXX followers, XXX engagements
"@genejchan DMD is not within his field of competence. He talked up/long $SRPT. If he were competent in this field he would short it not long it"
X Link 2025-12-05T01:22Z XXX followers, XXX engagements
"The future is complementary. CAPR does not bring back muscles and functions MSCLF can and the early results spoke for themselves. Soon we will know if the adults can sustain and gain more and P2 is starting in days with blinded interim in Q2. In an ideal world we could have the patients live into old age if both drugs work"
X Link 2025-12-11T01:09Z XXX followers, XXX engagements
"@charle77238 There is a budget in their disclosure on Canadian side. They are guiding for 33M spending for P2 and leaving out a couple millions in reserve. So they have the cash. If they are short on cash I would never recommend"
X Link 2025-12-11T12:09Z XXX followers, XX engagements
"So $RNA's exon44 functional data just dropped. NSAA change from baseline is ZERO in an open label setting. Knowing open label data typically outperform in open label what would have happened if this was RCT I dare say they would have failed. Critically how is is possible that an exon skipper with average expression of 30%+ with some patients reaching as high as 50%+ fail to show ANY functional benefit at all in NSAA Remember this is well into Beckers territory if not beyond. If exonskipping or uDys or any drug that is built on the membrane stability hypothesis could bring function back this"
X Link 2025-12-02T02:45Z XXX followers, XXX engagements
"$MSCLF's 2nd indication will be FSHD. They did have mice data showing strength improvements but to me DMD is the clear shot on goal. The rest is optionality/platform value"
X Link 2025-12-12T04:17Z XXX followers, XXX engagements
/creator/x::FidelisAurelius